| 19th week of 2009 patent applcation highlights part 36 |
| Patent application number | Title | Published |
|---|
| 20090117092 | COLLAGENOLYTIC ACTIVE ENZYME CONTAINING COMPOSITIONS, AND THEIR USE IN THE DENTAL FIELD - The invention relates to a composition comprising at least one collagenolytic active enzyme with enzymatic activity at acidic pH for drilless enzymatic caries removal. Furthermore, the present invention relates to a process of producing this collagenolytic active enzyme comprising composition and to processes of removing caries. The invention also relates to the use of collagenolytic active enzyme comprising compositions for producing a treatment agent for dental applications. | 2009-05-07 |
| 20090117093 | GRANULYSIN PEPTIDES AND METHODS OF USE THEREOF - Granulysin peptides are small antimicrobial agents with potent activity. A pharmaceutical composition comprising granulysin peptides as an active agent is administered therapeutically to a patient for exfoliation, e.g. for the treatment of skin lesions. | 2009-05-07 |
| 20090117094 | Method Of Making The Porous Carbon Material And Porous Carbon Materials Produced By The Method - A method for making the microporous carbon with modified pore size distribution and advanced sorption behaviour. The carbon is derived from metal or metalloid carbides. The method employs the use of oxidant in reaction medium that during the carbide conversion into carbon widens small micropores, which otherwise would be hardly accessed by sorbing molecules or ions in practical applications. The microporous carbon obtained is free of impurities and possesses extremely narrow pore size distribution. | 2009-05-07 |
| 20090117095 | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia - Provided are isolated and purified preparations of a combination of a light chain antibody gene and a heavy chain antibody gene, where the light chain and heavy chain antibody genes are the same among more than one patient with B cell chronic lymphocytic leukemia (B-CLL). Vectors comprising those genes and cells comprising those vectors are also provided, as are isolated and purified antibodies encoded by the antibody genes. Anti-idiotype antibodies, peptides, and aptamers that bind to the antigen-binding region of an antibody encoded by the antibody genes are additionally provided, as are multimeric molecules comprising multiple binding sites that bind to the antigen-binding region of an antibody encoded by the antibody genes. Methods of determining whether a patient with B cell chronic lymphocytic leukemia (B-CLL) has a form of B-CLL that is susceptible to treatment directed to eliminating idiotype specific B cell receptor-bearing B-CLL cells are also provided, as are methods of following the progression of treatment of B-CLL in the patient. Additionally, methods of treating a patient having B-CLL are provided, as are methods of identifying a therapeutic agent for B-CLL. | 2009-05-07 |
| 20090117096 | METHODS AND COMPOSITIONS FOR INHIBITION OF METASTASIS - This invention generally relates to methods of producing an antibody phage population having affinity for a tumor cell target expressing a metastatic phenotype. The invention further relates to antibody compositions that specifically bind to a cell surface receptor on the metastatic cell. | 2009-05-07 |
| 20090117097 | Stabilizer for Protein Preparation Comprising Meglumine and Use Thereof - An objective of the present invention is to provide methods for stabilizing proteins and methods for suppressing protein aggregation, which comprise the step of adding for suppressing protein aggregation, which comprise meglumine. Still another objective of the present invention is to provide pharmaceutical compositions comprising antibody molecules stabilized by meglumine, methods for producing the pharmaceutical compositions, and kits comprising the pharmaceutical compositions. | 2009-05-07 |
| 20090117098 | Complement C1Q Inhibitors For The Prevention And Treatment Of Glaucoma - The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising a Complement C1q inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma, the composition comprising a pharmaceutically effective amount of a Complement C1q inhibitor. | 2009-05-07 |
| 20090117099 | EXTRACELLULAR HISTONES AS BIOMARKERS FOR PROGNOSIS AND MOLECULAR TARGETS FOR THERAPY - Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as biomarkers for prognosis of sepsis and other diseases. | 2009-05-07 |
| 20090117100 | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates - Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: | 2009-05-07 |
| 20090117101 | HEH4 Molecules and Uses Thereof - The present invention provides HEH4 polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing HEH4 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with HEH4 polypeptides. | 2009-05-07 |
| 20090117102 | Methods and compositions using CD3 agonists - Compositions of CD3 antibody and gastrin and uses thereof in the prevention and intervention of diabetes. | 2009-05-07 |
| 20090117103 | M-CSF Antibody compositions Having Reduced Levels of Endotoxin - The present invention provides for compositions of anti-M-CSF antibodies that are substantially free of endotoxin. Also provided are methods of treating M-CSF-mediated disorders with pharmaceutical formulations of anti-M-CSF antibodies having reduced endotoxin levels, including inflammatory diseases and neoplasia disorders. | 2009-05-07 |
| 20090117104 | GLP-2 Mimetibodies, Polypeptides, Compositions, Methods and Uses - Mammalian GLP-2 mimetibodies, polypeptides and nucleic acids are disclosed. Methods of utilizing the mimetibodies and polypeptides to treat GLP-2 related diseases are also disclosed. | 2009-05-07 |
| 20090117105 | HUMANIZED ANTI-VENEZUELAN EQUINE ENCEPHALITIS VIRUS RECOMBINANT ANTIBODY - A CDR grafted humanized rAb comprises a human Ig framework having CDRs from murine mAb 1A4A1 VH and VL. DNA sequences and vectors incorporating such sequences are also provided as are pharmaceutical preparations and methods of using the humanized rAbs. | 2009-05-07 |
| 20090117106 | Cancer Specific Glycans and Use Thereof - The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures. | 2009-05-07 |
| 20090117107 | Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases - The present invention relates to methods for identifying agents capable of inhibiting the expression or activity of proteins involved in the processes modulating osteoclastogenesis, which inhibition is useful in the prevention and/or treatment of bone and joint degenerative diseases and diseases involving aberrant activity or differentiation of osteoclasts. In particular, the present invention provides methods for identifying agents for use in the prevention and/or treatment of rheumatoid arthritis. | 2009-05-07 |
| 20090117108 | Gene Engineering Recombinant Anti-CEA, Anti-CD3, And Anti-CD28 Single-Chain Tri-Specific Antibody - The invention is related to a recombinant single-chain tri-specific antibody made from anti-Tumor Associated Antigen (TAA) antibody, FC interlinker, anti-CD3 antibody, HSA interlinker and anti-CD28 antibody in turn. Particularly, the invention relates to an anti-CEA, anti-CD3, anti-CD28 recombinant single-chain tri-specific antibody, CEA-scTsAb, which was constructed with three tandem antibody fragments (anti-CEA scFv, anti-CD3 scFv and anti-CD28 single-domain antibody) linked by two interlinkers (FC interlinker, HSA interlinker), and could be appended by C myc tag or histidine tag ((His) | 2009-05-07 |
| 20090117109 | Methods For Reducing Biofilm Formation In Infectious Bacteria - The present invention provides methods of preventing or inhibiting biofilm formation by a population of bacteria, said method comprising the administration to the population of an antibody to a lactone or lactone-derived signal molecule secreted by bacteria. The invention therefore also provides methods for the treatment of bacterial infection in biofilm formation is prevented or inhibited. | 2009-05-07 |
| 20090117110 | Method for the In Vitro Assessment of the Progression Status of an Infection by an HIV Virus in an Individual - The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. | 2009-05-07 |
| 20090117111 | USES OF ANTI-CD40 ANTIBODIES - Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided. The methods of the present invention find use in treatment of cancers and pre-malignant conditions that are associated with CD40-expressing cells. These methods are particularly advantageous with respect to cancers and pre-malignant conditions that are associated with cells expressing both CD40 and CD20, as the methods enable the treatment of patients having a cancer or pre-malignant condition that is refractory to therapy with other oncotherapeutic agents such as anti-CD20 antibodies. | 2009-05-07 |
| 20090117112 | IMMUNOMODULATORY COMPOSITIONS AND USES THEREFOR - The poxvirus proteins designated A41L and 130L bind to three receptor-like protein tyrosine phosphatases (RPTP), leukocyte common antigen related protein (LAR), RPTP-δ, and RPTP-σ, that are present on the cell surface of immune cells. When a host is infected with the poxvirus, binding of A41L to cell surface proteins on the host cells results in suppression of the immune response. The present invention provides agents such as antibodies, and antigen-binding fragments thereof, small molecules, aptamers, small interfering RNAs, and peptide-IgFc fusion polypeptides that interact with one or more of LAR, RPTP-δ, and RPTP-σ expressed by immune cells or interact with a polynucleotide encoding the RPTP. Also provided are RPTP Ig domain oligomers and Fc fusion polypeptides. Such agents are useful for treating an immunological disorder in a subject according to the methods described herein. | 2009-05-07 |
| 20090117113 | Immunogenic And Therapeutic Compositions For Streptococcus Pyogenes - Group A streptococcal (GAS) antigens useful for providing immunity against | 2009-05-07 |
| 20090117114 | IL-17 homologous polypeptides and therapeutic uses thereof - The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 2009-05-07 |
| 20090117116 | IMMUNOGENIC PEPTIDES AND METHODS OF USE FOR TREATING AND PREVENTING CANCER - Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e.g., alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor cell, methods of stimulating CD4 | 2009-05-07 |
| 20090117117 | TARGETING ABCB5 FOR CANCER THERAPY - The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof. | 2009-05-07 |
| 20090117118 | ANTIBODIES SPECIFIC FOR SCLEROSTIN AND METHODS FOR INCREASING BONE MINERALIZATION - Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures. | 2009-05-07 |
| 20090117119 | RTEF-1 VARIANTS AND THE USE THEREOF FOR INHIBITION OF ANGIOGENESIS - Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD). | 2009-05-07 |
| 20090117120 | Transgenic animal model for alzheimer's disease - Provided is a novel APP (amyloid precursor protein) transgenic non-human animal modeling in vivo the pathophysiological effects and effects on cognitive behavior of early intraneuronal and extracellular brain parenchymal amyloid-β (Aβ) deposition and cerebral amyloid angiopathy associated with brain microhemorrhages and reduced vasoreactivity and blood flow. Furthermore, methods of screening for therapeutic or diagnostic agents useful in the treatment or diagnosis of Alzheimer's disease, in particular for improving blood flow to the brain are provided as well as the corresponding therapeutic methods. | 2009-05-07 |
| 20090117121 | Pseudomonas Aeruginosa Outer Membrane Protein PA0427 - An object of the present invention is to provide a protein or peptide antigen and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with | 2009-05-07 |
| 20090117122 | Resistin Antagonists and Their Use - Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are also disclosed. Antigens useful for raising antibodies against human resistin are also disclosed. | 2009-05-07 |
| 20090117123 | IMMUNOPEPTIDES OF HPV E6 AND E7 PROTEINS - An immunopeptide containing a cytotoxic T lymphocyte epitope derived from HPV E6 or HPV E7 protein. The immunopeptide can be used as a component of a vaccine for enhancing immune responses against HPV or treating HPV-associated diseases. Also within the scope of this invention are a nucleic acid encoding the immunopeptide and an antibody specific to the CTL epitope. | 2009-05-07 |
| 20090117124 | Anti-IgE antibodies - The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies. | 2009-05-07 |
| 20090117125 | SYNTHESIS OF 8H-3A-AZA-CYCLOPENTA[A]INDENES AND 5,10-DIHYDROPYRROLO[1,2-B]ISOQUINOLINES DERIVATIVES AND THEIR USE AS ANTITUMOR THERAPEUTIC AGENTS - The present disclosure relates to a series of bis(hydroxymethyl) and its bis(carbamate) of 8H-3a-azacyclopenta[a]indene-1-yl and 5,10-dihydropyrrolo-[1,2-b]isoquinolines derivatives (Formula I-Formula IV) as DNA di-alkylating agents. The preliminary antitumor studies indicated that compounds disclosed herein could exhibit potent cytotoxicity in vitro and antitumor therapeutic efficacy in human tumor xenografts and could have little or no cross-resistance to either Taxol or Vinblastine. The results demonstrated that compounds disclosed herein possess potent antitumor therapeutic efficacy and are expected to have potential for clinical applications. | 2009-05-07 |
| 20090117126 | Neutralising Antibody Molecules Having Specificity for Human IL-17 - The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. | 2009-05-07 |
| 20090117127 | Novel Compounds and Methods for Their Production - The present invention relates to 11-O-desmethylmacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies. | 2009-05-07 |
| 20090117128 | Anti-HPA - The present invention relates to a monoclonal antibody selectively recognizing a human platelet alloantigen, a method for detecting the presence or absence of at least one human platelet alloantigen using said antibody, a method for the production of said antibody, a pharmaceutical composition comprising said antibody, and a kit containing said antibody. | 2009-05-07 |
| 20090117129 | Immunogen adherence inhibitor directed to lactobacillus organisms and method of making and using it - A microbial adherence inhibitor specific to lactic acid producing microorganisms, in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment or adherence of colony-forming immunogens in the fermentators. The inhibitor is made by inoculating female birds with the immunogen, allowing time for an immune response in the female bird and then harvesting the eggs that contain antibodies to the immunogen. The egg contents can be dried or used as a liquid and added to the media in the fermentators. Dependent upon the particular immunogen with which the female bird is inoculated, the egg antibody will specifically bind to the specific immunogen. When bacteria such as | 2009-05-07 |
| 20090117130 | KALLIKREIN-INHIBITOR THERAPIES - Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient. | 2009-05-07 |
| 20090117131 | Pharmaceutical Composition for The Treatment or Prevention of Allergic Diseases, Use Thereof, and A Method for The Treatment or Prevention of Allergic Diseases - The present invention provides a pharmaceutical composition for preventing or treating allergic diseases comprising histamine and allergen-specific antibody as active ingredients. Also, the present invention provides a use of the above composition for the manufacture of medicament for preventing or treating allergic diseases. Further, the present invention provides a method of preventing or treating allergic diseases which comprises administrating the above pharmaceutical composition to a mammal. When the pharmaceutical composition of the present invention is administered to a mammal, a specific allergic immune response (hypersensitive immune response) to antigen inducing allergic reaction (allergen) that can not be effectively controlled by current standard pharmacological treatments can be effectively suppressed. Therefore, refractory allergic diseases that cannot be sufficiently improved by the current standard pharmacological treatments can be effectively improved if the pharmaceutical composition of the present invention, its use for preventing or treating allergic diseases, or a method of preventing or treating allergic diseases by the above composition is applied. | 2009-05-07 |
| 20090117132 | Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment - The invention relates to administration of an anti-CTLA-4 antibody, particularly human antibodies to human CTLA-4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and MDX-010, in combination with an immunostimulatory nucleotide, i.e, CpG ODN PF3512676, for treatment of cancer. The invention relates to administering a combination of an anti-CTLA-4 antibody and CpG ODN PF3512676 as neoadjuvant, adjuvant, first-line, second-line, and third-line therapy of cancer, whether localized or metastasized, and at any point(s) along the disease continuum (e.g, at any stage of the cancer). | 2009-05-07 |
| 20090117133 | POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW AFFINITY FCyRECEPTORS - The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG | 2009-05-07 |
| 20090117134 | Truncated EGF Receptor - The present invention relates to truncated EGF receptor molecules that exhibit increased binding affinities for EGFR ligands such as EGF and TGF1. The present invention also relates to methods of screening for EGF receptor ligands and methods of treatment which involve the use of these molecules. | 2009-05-07 |
| 20090117135 | VACCINE COMPRISING AN ANTIGEN CONJUGATED TO LOW VALENCY ANTI-CD40 OR ANTI-CD28 ANTIBODIES - We describe a conjugate comprising an antibody and antigen wherein said conjugate has low antibody valency and including methods to prepare said conjugate. | 2009-05-07 |
| 20090117136 | Recombinant allergen - Dander from the domestic cat ( | 2009-05-07 |
| 20090117137 | PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 2009-05-07 |
| 20090117138 | VACCINE FOR A THERAPEUTIC OR A PROPHYLACTIC TREATMENT OF MYASTHENIA GRAVIS - Complementary peptide having at least a sequence complementary to a major immunogenic region of an acetylcholine receptor involved in myasthenia gravis, characterized in that the complementary peptide has at least a sequence SEQ. ID. NO1 with a tryptophan in position 8, carrying at least one optionally substituted hydrocarbon group. Therapeutic composition comprising the Complementary peptide according to the invention and use thereof for manufacturing a vaccine to be used in a therapeutic or prophylactic treatment of myasthenia gravis in mammals. | 2009-05-07 |
| 20090117139 | LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHODS OF USE - Substantially purified salivary | 2009-05-07 |
| 20090117140 | Human papilloma virus dominant CD4 T cell epitopes and uses thereof - Provided herein are methods of determining immunodominant T cell epitopes within a protein expressed in an individual and immunotherapy directed towards a protein in an individual using these determined epitopes. The method comprises administering autologous dendritic cells pulsed with a recombinant protein to the individual, establishing T-cell lines therefrom and incubating the T cell lines with representative peptides from the protein to measure and identify those peptides from the protein inducing the T cell response. Also provided are synthetic or recombinant peptides or immunogenic compositions thereof comprising the identified peptide(s) or peptides of similar sequence and a method of preventing or treating a pathophysiological condition. | 2009-05-07 |
| 20090117141 | HIV VACCINE COMPOSITION - An anti-HIV vaccine composition is disclosed. The vaccine comprises an combination of immunogenic peptide mixtures, which mixtures may be prepared in a single synthesis. The composition collectively represents the in vivo variability seen in immunogenic epitopes from highly variable regions of HIV. Immunization with the vaccine elicits broadly reactive immunity (CTL and T helper cell responses) against the divergent strains of HIV upon which it is based. The vaccine may be formulated to target regionally distinct variability based on an HIV clade predominant in a geographical region. | 2009-05-07 |
| 20090117142 | RECOMBINANT FUSOBACTERIUM NECROPHORUM LEUKOTOXIN VACCINE AND PREPARATION THEREOF | 2009-05-07 |
| 20090117143 | Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens - An immunogenic composition comprising a recombinant protein comprising a | 2009-05-07 |
| 20090117144 | Recombinant flu vaccines - The present invention provides compositions for use as vaccines against the influenza virus, and rapid methods of producing such compositions. The composition include i) at least one peptide derived from an influenza virus, wherein the peptide is fused to a capsid protein derived from a plant virus forming a recombinant capsid fusion peptide and ii) at least one isolated antigenic protein or protein fragment derived from a human or avian influenza virus. The isolated antigenic protein or protein fragment derived from the human or avian influenza virus can be conjugated to the surface of the recombinant capsid fusion peptide. | 2009-05-07 |
| 20090117145 | Composition and Method For Enhancing Immune Response - A composition and method for enhancing immune response in a living organism is disclosed. In particular, the present disclosure provides an adjuvant peptide for use in raising an immune response to an antigen. The adjuvant peptide is selected from a group of peptides with an HIV-related sequence. Additionally, the adjuvant peptide can comprise a fusion-protein that acts as a mucosal adjuvant. The adjuvant peptide can be transformed into one or more living cells, such that the mucosal adjuvant can be produced in living cells and then administered by systemic, mucosal or epidermal delivery. | 2009-05-07 |
| 20090117146 | SYSTEM AND METHOD FOR PROMOTING HAIR GROWTH AND IMPROVING HAIR AND SCALP HEALTH - A system is provided for promoting hair growth comprising one or more extracts from a steroidal alkaloid-containing plant selected from a | 2009-05-07 |
| 20090117147 | VACCINES COMPRISING OUTER MEMBRANE VESICLES FROM GRAM NEGATIVE BACTERIA - The present invention relates to the field of vaccine formulation, particularly the field of novel adjuvant compositions comprising outer membrane vesicles (or blebs), and advantageous methods of detoxifying these compositions, and advantageous methods of use of such adjuvants. | 2009-05-07 |
| 20090117148 | Capsular Polysaccharides Solubilisation and Combination Vaccines - Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1. | 2009-05-07 |
| 20090117149 | NOVEL ATTENUATED VIRUS STRAINS AND USES THEREOF - Methods and compositions concerning mutant flaviviruses with reduced virulence. In some embodiments the invention concerns nucleotide sequences that encode mutant flaviviral proteins. Viruses comprising mutant NS1 and NS4B genes display reduced virulence are provided. In further aspects of the invention, flavivirus vaccine compositions such as West Nile virus vaccines are provided. In another embodiment the invention provides methods for vaccination against flavivirus infection. | 2009-05-07 |
| 20090117150 | Functional Mutations In Respiratory Syncytial Virus - The present invention provides recombinant respiratory syncytial viruses that have an attenuated phenotype and that comprise one or more mutations in the viral P, M2-1 and/or M2-2 proteins, as well as live attenuated vaccines comprising such viruses and nucleic acids encoding such viruses. Recombinant RSV P, M2-1 and M2-2 proteins are described. Methods of producing attenuated recombinant RSV, and methods of quantitating neutralizing antibodies that utilize recombinant viruses of family Paramyxoviridae, are also provided. | 2009-05-07 |
| 20090117151 | VECTOR FOR ANTI-HPV VACCINE AND TRANSFORMED MICROORGANISM BY THE VECTOR - Expression vectors that can efficiently produce virion capsid protein, tumor-associated protein of human papillomavirus on a microbial surface. Bacterial strains harboring such surface display vectors, and the use of the bacterial strains or their extracts or purified products as complex vaccines, are also described. The surface display vectors contain one or more than two genes selected from among pgsB, pgsC and pgsA, encoding a poly-χ-glutamic acid synthetase complex (pgsBCA) of a | 2009-05-07 |
| 20090117152 | Mycoplasma Hyopneumoniae Avirulent Adjuvanted Live Vaccine - Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating | 2009-05-07 |
| 20090117153 | Disulfide Trap MHC Class I Molecules and Uses Therefor - A disulfide trap, comprising an antigen peptide covalently attached to an MHC class I heavy chain molecule by a disulfide bond extending between two cysteines, is disclosed. In some configurations, a disulfide trap, such as a disulfide trap single chain trimer (dtSCT), can comprise a single contiguous polypeptide chain. Upon synthesis in a cell, a disulfide trap oxidizes properly in the ER, and can be recognized by T cells. In some configurations, a peptide moiety of a disulfide trap is not displaced by high-affinity competitor peptides, even if the peptide binds the heavy chain relatively weakly. In various configurations, a disulfide trap can be used for vaccination, to elicit CD8 T cells, and in multivalent MHC/peptide reagents for the enumeration and tracking of T cells. Also disclosed are nucleic acids comprising a sequence encoding a disulfide trap. Such nucleic acids, which can be DNA vectors, can be used as vaccines. | 2009-05-07 |
| 20090117154 | SYNTHETIC POLYVALENT CARBOHYDRATES AS COMPONENTS OF MICROBICIDES - Inhibitors that block the DC-SIGN mediated transmission of the HIV-virus from mucosal infection sites to T-lymphocytes. In one embodiment, the inhibitors include at least one oligosaccharide chain attached to a scaffolding framework in which the number of the oligosaccharide chains attached to the scaffold can be 2, 3, 4 or more. In another embodiment, HIV-I viral infection is treated by administration of a composition including a therapeutically effective amount of an oligosaccharide cluster and/or oligosaccharide/protein cluster binding DC-SIGN, to inhibit DC-SIGN from binding to HIV envelope glycoprotein. | 2009-05-07 |
| 20090117155 | TREATMENT OF HIV-1 BY MODULATION OF VPR ACTIVATION OF THE M-CSF PROMOTER - Macrophage colony-stimulating factor (M-CSF) is important for human immunodeficiency virus-type 1 (HIV-1) infection, replication and survival of infected cells. The mechanism(s) by which HIV-1 infection increases M-CSF production are, however, poorly understood. Here, we report that HIV-1 Vpr enhances M-CSF promoter activity and production in primary human monocytes and macrophages. Vpr activates M-CSF transcription through four C/EBP beta binding sites present within the M-CSF promoter, possibly through increased phosphorylation of C/EBP beta. RU486 (mifepristone) blocked Vpr-mediated up-regulation of M-CSF, suggesting that Vpr activates M-CSF promoter activity via the glucocorticoid pathway. The invention provides new avenues for therapeutic interventions in HIV-1 infection and other diseases involving M-CSF dysregulation (including malignancy, osteoporosis, autoimmune disorders, arthritis, and obesity) using glucocorticoid antagonists and modulators of C/EBP beta activity. | 2009-05-07 |
| 20090117156 | GENE THERAPY FOR NIEMANN-PICK DISEASE TYPE A - This disclosure pertains to methods and compositions for tolerizing a mammal's brain to exogenously administered acid sphingomyelinase polypeptide by first delivering an effective amount of a transgene encoding the polypeptide to the mammal's hepatic tissue and then administering an effective amount of the transgene to the mammal's central nervous system (CNS). | 2009-05-07 |
| 20090117157 | METHODS OF TREATING UROGENITAL-NEUROLOGICAL DISORDERS USING MODIFIED CLOSTRIDIAL TOXINS - The present specification discloses modified Clostridial toxins, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such modified Clostridial toxins and compositions. | 2009-05-07 |
| 20090117158 | Transdermal sustained release drug delivery - Provided herein are microprojections and microprojection arrays wherein a microprojection is coated with at least two layers. One layer comprises a biologically active agent, for example, a PTH agent and optionally other excipients. Another layer, which is generally, initially devoid of active agent comprises a polymer or a mix of polymers to provide controlled release, for example sustained release, of the biologically active agent contained in the first layer. Microprojections coated with multiple layers, some layers containing a biologically active agent and other layers containing a polymer for controlled release are also contemplated herein. | 2009-05-07 |
| 20090117159 | PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE - The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation. | 2009-05-07 |
| 20090117160 | Compositions for Making up Keratinous Materials - The present invention relates to a kit comprising:
| 2009-05-07 |
| 20090117161 | SEMICONDUCTOR-BASED CORE-SHELL PARTICLES FOR BLOCKING ELECTROMAGNETIC RADIATION - A plurality of particles for blocking electromagnetic radiation wherein each particle includes at least one semiconductor core encased within a shell, the semiconductor cores being of substantially uniform diameter, which diameter is selected according to the quantum size effect such that radiation incident on the particles is absorbed below a preselected radiation wavelength. In particular embodiments, the diameter may not vary between cores by more than a preselected percentage, and the diameter may fall within the range of approximately one to approximately five nanometers. Each particle may have a single semiconductor core surrounded by a single shell or a plurality of semiconductor particles surrounded by a single shell. In other embodiments, the particles may be created by forming at least one semiconductor core in a first reaction zone and forming a shell encapsulating the at least one semiconductor core in a second reaction zone. A plurality of semiconductor cores may optionally be agglomerated together before the shell is formed. | 2009-05-07 |
| 20090117162 | Topical Cosmetic Compositions - Disclosed is a cosmetic composition for topical application to the skin. The cosmetic composition comprises micron-sized, polymer-coated glass ball lenses having a polymer coating on the exterior surface thereof. The polymer-coated glass ball lenses are enhanced by engineered illumination and optics, and the appearance of the skin to which the cosmetic is applied is observable without masking the underlying skin. | 2009-05-07 |
| 20090117163 | Composition and Method for the Application of Human Synthetic Pheromones Using Substance Slowly Releasing Technological Bio Capsule in form of Drops in Clothing, Underwear, Jewels and Like - The invention regards a composition for the application of human synthetic pheromones in clothing, underwear, jewels, and like, comprising at least three positive human substances, e.g. androstenone, androstenediol and/or androsterone, said composition being predisposed in said clothing, underwear, jewel or like in such way to be diffused by the user by means of a simple action. The invention regards moreover a method for the application and dispensation of said composition, use of the same composition, to clothing, underwear, jewels and like incorporating the composition and a capsule as a carrier for the same composition. | 2009-05-07 |
| 20090117164 | Disinfectant with Durable Activity Based on Alcohol-Soluble Quaternary Ammonium Polymers and Copolymers - An alcohol- or glycol-soluble, water-insoluble, disinfectant composition and a method of using the same for disinfecting and for providing a prolonged antimicrobial property to a variety of surfaces, including skin. The composition comprises at least one alcohol or glycol and an antimicrobial polymer that is capable of imparting an antimicrobial property to a surface without the use of a metal or a metal-containing compound. The composition is applied to a surface and allowed to evaporate leaving a coating of antimicrobial polymer. Alternatively, the composition is incorporated into or within the substrate. | 2009-05-07 |
| 20090117165 | DECONTAMINATION SYSTEM AND METHOD OF DECONTAMINATION - In one embodiment, a pad is provided for wiping a contaminant from a contaminated surface. The pad includes a layer of non-adsorptive fabric having a first surface configured to directly contact the contaminated surface, and a second surface opposite to the first surface. The pad further includes a layer of activated-carbon fabric attached to the second surface of the layer of non-adsorptive fabric. A decontamination liquid that is a solvent for the contaminant saturates the layer of non-adsorptive fabric and the layer of activated-carbon fabric. Such decontamination liquid is configured to adsorb the contaminant. The layer of activated-carbon fabric is configured to adsorb the contaminant from the decontamination liquid, and the layer of non-adsorptive fabric is configured to prevent direct contact of the activated-carbon fabric and any adsorbed contaminant in the activated-carbon fabric with the contaminated surface. | 2009-05-07 |
| 20090117166 | Sequential coupling of biomolecule layers to polymers - A bio-mimetic or bio-implantable material based on a sequential process of coupling biomolecule layers to a polymer layer is provided. In general, the material could be based on two or more biomolecule layers starting with one of the layers covalently linked to the polymer layer via cross-linkers and the other layers sequentially and covalently linked using cross-linkers to the previously added layer. The polymer layer could be a hydrogel or an interpenetrating polymer network hydrogel. The first layer of biomolecules could be a collagen type, fibronectin, laminin, extracellular matrix protein, or any combinations thereof. The second layer of biomolecules typically is a growth factor, protein or stimulant. The cross-linkers are either water soluble or insoluble bifunctional cross-linkers or azide-active-ester crosslinkers. The material and process as taught in this invention are useful in the field of tissue engineering and wound healing. | 2009-05-07 |
| 20090117167 | Injectable capsaicin with vasocontrictor adjunctive agent - Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and coadministering a vasoconstrictor. | 2009-05-07 |
| 20090117168 | Device and method for attaracting diseased cells and foreign substances - An implantable device for attracting diseased cells or foreign substances circulating within bodily fluid channels is disclosed. The device comprises a frame, an attachment means for maintaining the frame in a localized position in a body vessel, and at least one attractant on the frame, where the attractant is capable of attracting a diseased cell or a foreign substance. The device may also include a therapeutic agent The device may be used for diagnosis, disease containment or treatment. The device may also be used for attracting and localized treatment of diseased cells and foreign substances. | 2009-05-07 |
| 20090117169 | Methods and compositions for regulating proliferation and migration of vascular smooth muscle cells - Provided is an extracellular domain of a mammalian Fat1 (Fat1 | 2009-05-07 |
| 20090117170 | SEGMENTED DEVICE FOR THE DELAYED RELEASE OF MOLECULES IN A TANGENTIAL DIRECTION THROUGH THIN FILMS AND USES THEREOF - The present invention of a segmented release device (sandwich construction with reservoir) for molecules (active compounds, medicaments, diagnostic, therapeutic and chemical reagents) is based on a construction which makes possible a constant release rate through diffusion-permeable intersegment films partially or completely filled with liquid of the neighboring media. The molecules pass here from the reservoir of the device into the outer medium by diffusion exclusively through the intersegment films. These intersegment films are adjustable in their thickness and composition in the manner specified in each case. | 2009-05-07 |
| 20090117171 | Compositions and methods for treatment of macular degeneration and related conditions - The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. The methods comprise administering a composition comprising a compound that is an antagonist of a G protein coupled receptor, e.g., the C5a receptor, to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization. The invention provides compositions comprising a compound that is an antagonist of a G protein coupled receptor linked either directly or indirectly to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization. | 2009-05-07 |
| 20090117172 | ORAL DELIVERY VEHICLE AND MATERIAL - Compositions for an oral delivery vehicle are described as well as methods for their manufacture and administration. The oral delivery vehicles can be made in any size or shape and can further comprise a medicament or other substance or object to be orally delivered. The vehicle can, for example, take the form of a pouch or capsule. Alternatively, a medicament or other substance to be orally delivered can be coated with the composition. In another alternative, the medicament or other substance to be orally delivered can be dispersed within a matrix of the composition. The compositions for the oral delivery vehicle are also suitable for use as an animal food or treat or use as a hunting bait or lure. | 2009-05-07 |
| 20090117173 | Antimicrobial glaze and poreclain enamel via double layer glaze with high zinc content - A cost-effective and practical antimicrobial glaze system and glazing process is disclosed herein. The antimicrobial glaze/enamel may comprise at least two layers: a base layer and a top layer. The base layer may contain a typical or normal glaze widely used in sanitary ware, having a low level of zinc oxide. The base layer glaze may be directly sprayed on the clay body surface. A thin top glaze layer is sprayed on top of the base glaze layer and the top layer may contain a high level of zinc oxide. | 2009-05-07 |
| 20090117174 | MODIFIED SORBITAN SILOXANE COMPOSITIONS AND USE THEREOF - The present disclosure generally relates to personal care compositions and wipes. More particularly, the disclosure relates to compositions and wipes for imparting a perceivable aesthetic feel to the skin of a user. To achieve the perceivable aesthetic feel, a modified sorbitan siloxane is incorporated into the compositions and wipes. | 2009-05-07 |
| 20090117175 | HEMOSTATIC COMPOSITIONS AND THERAPEUTIC REGIMENS - The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to treat wounds. More specifically the present invention relates to hemostatic compositions that reduce the need for, and cost of, nursing care of patients with chronic wounds by reducing the frequency of wound dressing changes. | 2009-05-07 |
| 20090117176 | Anticancer Treatments - A method of treating the human body for cancer comprises administering an effective therapeutic amount of a Pegylated Liposomal form of the anthracycline Doxorubicin (“PLD”), in combination with an effective therapeutic amount of ET-743 | 2009-05-07 |
| 20090117177 | Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents - Described are methods and compositions for treating tumors, such as drug-sensitive tumors, inoperable tumors, poorly vascularized tumors, and multidrug resistant tumors, by intravenous or direct intratumoral injection of compositions comprising microemulsions and polymeric micelle-encapsulated biologically active agents. The methods and compositions also include microemulsions converting into microbubbles in situ upon injection. The methods disclosed optionally including applying a micelle disruption method such as ultrasound. Also disclosed are methodologies of imaging administration of agents in tissues using streams of microemulsions which create microbubbles in situ upon injection. The methods and compositions also include enhancement of tumor treatment through use of microemulsions which create microbubbles in situ, upon injection, as cavitation nuclei. The methods and compositions are also useful in enhancing intracellular drug delivery. | 2009-05-07 |
| 20090117178 | PEPTIDE EPITOPES OF APOLIPOPROTEIN B - The present invention relates to antibodies raised against fragments of apolipoprotein B, in particular defined peptides thereof, for immunization or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, using one or more of said antibodies. | 2009-05-07 |
| 20090117179 | siDNA against Influenza Virus - Silencing of Influenza virus RNA can be achieved by siDNA. These are oligodeoxynucleotides having an antisense-strand homologous to the viral RNA and a second strand, partially complementary to the antisense-strand. The two strands are preferentially linked by a linker (eg 4 thymidines). Triple-helix formation with the target RNA is a preferred effect. The siDNA is superior to siRNA because it acts earlier, is easier taken up by the cell, the formation of RNA-DNA hybrids is preferred over double-stranded DNA or double-stranded RNA, which forms as tertiary structures in RNA genomes. Also the induction of interferon is less likely. siDNA is easier to synthesize and it is more stable. It can be combined with siRNA. | 2009-05-07 |
| 20090117180 | STABLE DIGESTIVE ENZYME COMPOSITIONS - Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 9% or less or 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 25%, about 20%, about 15% or about 10% after six months of accelerated stability testing and the titer level of a viral contaminant present in the pancreatin is at least about 1000 times less than the titer level of the viral contaminant present in a preparation from which the pancreatin is obtained. | 2009-05-07 |
| 20090117181 | Tablet comprising fluvastatin and carmellose calcium - The present invention relates to a fluvastatin-containing tablet, particularly a fluvastatin-containing tablet which has excellent disintegrating property and good bioavailability. | 2009-05-07 |
| 20090117182 | INTRAORALLY RAPIDLY DISINTEGRATING TABLET - The present invention provides an intraorally rapidly disintegrating tablet that can be formed using an ordinary apparatus, that has hardness with no practical problem and that disintegrates rapidly with good feeling in the oral cavity. | 2009-05-07 |
| 20090117183 | ORAL CONTRACEPTIVE CONTAINING A GESTAGEN AND AN ESTROGEN COMBINED WITH PHARMACEUTICALLY ACCEPTABLE AUXILIARY AGENTS AND/OR EXCIPIENTS, BUT NOT CONTAINING LACTOSE, AND METHOD OF MAKING SAME - The method produces a lactose-free oral contraceptive composition containing a combination of a gestagen and an estrogen together with one or more pharmaceutically acceptable auxiliary agents and/or excipients. The contraceptive composition is a tablet, powder, or capsule that contains the gestagen and estrogen, filler material such as microcrystalline cellulose and a binder such as hydroxypropylcellulose, but no lactose. Preferably the gestagen is dienogest, chlormadinone acetate, or levonorgestrel and the estrogen is ethinylestradiol, 17β-estradiol, or estradiol valerate. A method is provided for improving the prophylaxis of lactose intolerance in women taking oral contraceptives. The oral contraceptive preparations for a standard 28-day cycle or for long-term use contain at least 21 daily dose units of the gestagen and the estrogen in a low-dosage but without lactose and at most 7 daily dose units containing no active ingredient or a placebo. | 2009-05-07 |
| 20090117184 | Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception - Gestagens, preferably dienogest, chlormadinone acetate or levonorgestrel, in combination with estrogens, for example ethinylestradiol, 17β-estradiol or estradiol valerate, and one or more pharmaceutically acceptable auxiliary agents/excipients provide lactose-free oral contraception. | 2009-05-07 |
| 20090117185 | 2-(Aminomethyl)-5-Chlorobenzylamide Derivatives and their use as Inhibitors of the Clotting Factor Xa - The invention relates to 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of coagulation factor Xa. The compounds are suitable for the treatment and prophylaxis of cardiovascular and thrombotic events. | 2009-05-07 |
| 20090117186 | TROFOSFAMIDE-CONTAINING FILM-COATED TABLETS AND METHOD FOR THE PRODUCTION THEREOF - The invention at hand concerns trofosfamide containing film-coated tablets for oral application and a procedure for their production. | 2009-05-07 |
| 20090117187 | METHOD OF TREATING OR PREVENTING TISSUE DETERIORATION, INJURY OR DAMAGE DUE TO CONGESTIVE HEART FAILURE - A method of treatment for treating, preventing, inhibiting or reducing tissue deterioration, injury or damage due to congestive heart failure disease, or for restoring tissue adversely affected by said disease, in a subject, includes administering to a subject an effective amount of a composition including a peptide agent including amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a peptide agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, in the tissue. | 2009-05-07 |
| 20090117188 | Methods of Augmenting or Repairing Soft Tissue - Methods of repairing or augmenting soft tissue in a subject are described. The methods include injecting into a subject composition comprising a biodegradable, polymerizable macromer, the macromer comprising a water soluble polymer modified with one or more biodegradable moieties; and polymerizing the macromer to provide a hydrogel, thus repairing or augmenting the soft tissue. | 2009-05-07 |
| 20090117189 | Method for the Production of Polymerized Nanoparticles and Microparticles by Ternary Agent Concentration and Temperature Alteration Induced Immiscibility - Polymerized drug delivery devices are described. Additionally, methods are described for producing and for using polymerized particles for use as drug delivery devices. | 2009-05-07 |
| 20090117190 | SUSTAINED-RELEASE PREPARATION - It is intended to provide a sustained-release pharmaceutical preparation with absorbability not dependent on pH. The sustained-release preparation is characterized by containing 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone or a salt thereof, as a pharmaceutically active ingredient, and containing a hydrogel base and an organic acid. | 2009-05-07 |
| 20090117191 | Controlled release tramadol formulations - A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient. | 2009-05-07 |
| 20090117192 | COMPOSITION FOR TRANSDERMAL ABSORPTION AND FORMULATION COMPRISING A POLYMERIC MATRIX FORMED THEREFROM - The inventive composition for transdermal absorption characterized by comprising a nonsteroidal anti-inflammatory drug as an active ingredient together with an alkali metal-containing alcohol derivative as a solubilizing agent for the active ingredient comprises a high concentration of the active ingredient while using only a small amount of the solvent, and a transdermal absorption formulation comprising a polymeric matrix formed from the composition is capable of maximizing the skin absorption of the active ingredient with minimal skin irritation. | 2009-05-07 |
